Q-omics provides the consensus-scored ZNF429 profile across patient tissues and cancer cell-line models. ZNF429 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ZNF429 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF429 RNA expression shows 20,666 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, THCA, and UVM as cancer lineages where ZNF429 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF429 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF429 survival associations across molecular data types. ZNF429 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF429 RNA expression–survival associations across cancer types. High ZNF429 expression shows favorable associations in OV, KIRC, MESO, ACC, LUAD and KIRP. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for ZNF429 RNA expression.
This table summarizes ZNF429 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF429. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF429 shows lower tumor expression in THCA, COAD, HNSC, LUSC, KICH and LUAD. The THCA box plot shows higher ZNF429 RNA expression in normal versus tumor tissue (log2 FC = −1.285, t-test p < 0.001).
This table shows molecular features associated with ZNF429 in patient tissues and cancer cell lines. In patient samples, ZNF429 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF429 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
